ClinicalTrials.gg
RecruitingNCT06911099Updated Apr 6, 2025

Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR)

An observational study in Atrial Functional Mitral Regurgitation and Mitral Insufficiency, sponsored by University Hospital of Cologne. Recruiting at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by University Hospital of Cologne · Observational

How we know

From the registry’s dates

  • Started Jan 2010; still recruiting 16 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Mitral Valve Insufficiency with a site in Germany — 24 open to participants now, 32 under way, none of them phase 3. Mitral Valve Insufficiency · Germany.

Planned enrollment
6th of 33
1,000 · median 214
Started
2010
the only one that year
Observational
33 of 81
12 open now
Primary completion
2030-12
later than 26 of 31 live
Registered
76th of 81
by date

Among the 81 studies in Mitral Valve Insufficiency with a site in Germany, this one is the 6th largest by planned enrollment of the 33 observational ones that give a count, is the only one that started in 2010, is one of 33 observational ones, reaches primary completion later than 26 of the 31 other live ones, and was the 76th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

24 of the 81 studies in Mitral Valve Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Mitral Valve Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This investigator-initiated, multicenter, international, retrospective registry aims to investigate outcomes of patients with atrial functional mitral regurgitation, as treated in clinical routine.

03

Conditions studied

  • Atrial Functional Mitral Regurgitation
  • Mitral Insufficiency

Keywords

  • atrial functional mitral regurgitation
  • AFMR
  • atrial secondary mitral regurgitation
  • ASMR
  • mitral valve transcatheter edge-to-edge repair
  • M-TEER
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study aimes to include all patients with clinically significant mitral regurgitation of the atrial functional mitral regurgitation subtype, irrespective of the subsequent therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • functional mitral regurgitation
  • ≥50%

Exclusion criteria

Exclusion Criteria:

  • age under 18 years
  • known regional wall movement disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Mitral Valve Transcatheter Edge-to-Edge Repair (M-TEER)

    Patients who underwent mitral valve transcatheter edge-to-edge repair. All devices may be included.

  • Guideline Directed Medical Therapy

    Patients who underwent conservative management with guideline directed medical therapy.

  • Transcatheter Mitral Valve Replacement (TMVR)

    Patients who underwent transcatheter mitral valve replacement. All devices may be included.

06

What researchers measure

Primary outcomes

  1. Composite of all-cause mortality and heart-failure related rehospitalitzation

    Time frame: 12 months

Secondary outcomes

  1. Residual Mitral Regurgitation ≤1+

    Rate of patients achieving residual mitral regurgitation ≤1+ measured by transthoracic echocardiography. Assessment of mitral regurgitation severity according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease.

    Time frame: 12 months

  2. All-cause mortality

    Time frame: 12 months

  3. Cardiovascular mortality

    Time frame: 12 months

  4. Heart failure related rehospitalization

    Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization.

    Time frame: 12 months

  5. Unplanned mitral valve intervention

    Incidence of unplanned surgical or transcatheter re-intervention, heart transplantation or left ventricular assist device implantation.

    Time frame: 12 months

  6. New York Heart Association (NYHA) class III or IV

    Assessment of New York Heart Association (NYHA) classification stage (in- or outpatient), with the minimum of I (no symptoms) and the maximum of IV (dyspnea at rest), with higher values indicating worse functional capacity.

    Time frame: 12 months

  7. 6 Minute Walking Distance

    Time frame: 12 months

07

Study locations

22 of 22 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2010 (actual). Primary completion is estimated for Dec 2030, 251 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 4, 2025
StartActual
Jan 1, 2010
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2035
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06911099
Lead sponsor
University Hospital of Cologne
Responsible party
Philipp von Stein (MD, University Hospital of Cologne) — Principal investigator
First posted
Apr 4, 2025
Start date
Jan 1, 2010
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Apr 6, 2025

Study contacts

Philipp von Stein, MD
Contact
philipp.von-stein@uk-koeln.de
646-321-8145
Christos Iliadis, MD
Contact
christos.iliadis@uk-koeln.de
+49-221-478-32401
Christos Iliadis, MD
principal investigator · Heart Center, Department III of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion